The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AZTA | -27.34% | -34.49% | -8.11% | +304% |
| S&P | +14.5% | +93.32% | +14.09% | +1,317% |
Azenta, Inc. is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples. The Life Sciences Services segment focuses on the solutions addressing the many needs of customers in the area of genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development markets. The company was founded in 1978 and is headquartered in Burlington, MA.
The company's underwhelming third-quarter earnings forecast is weighing on its shares.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $143.94M | -16.7% |
| Gross Profit | $67.76M | 8.5% |
| Gross Margin | 47.07% | 10.9% |
| Market Cap | $1.41B | -50.3% |
| Market Cap / Employee | $0.47M | -42.1% |
| Employees | 3K | 0.0% |
| Net Income | $0.68M | 110.3% |
| EBITDA | $16.30M | 63.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $272.35M | -19.7% |
| Accounts Receivable | $164.64M | -15.4% |
| Inventory | 80.5 | -30.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $52.63M | -13.2% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1.47% | 4.3% |
| Return On Invested Capital | -2.78% | -2.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $14.97M | 411.8% |
| Operating Free Cash Flow | $25.81M | 1341.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.23 | 1.29 | 0.92 | 0.83 | -35.95% |
| Price to Sales | 3.55 | 3.51 | 2.50 | 2.33 | -44.95% |
| Price to Tangible Book Value | 2.31 | 2.75 | 1.70 | 1.55 | -31.15% |
| Price to Free Cash Flow TTM | 180.58 | 111.65 | 61.17 | 30.85 | -54.68% |
| Enterprise Value to EBITDA | 150.83 | 293.21 | 199.15 | 69.96 | -69.06% |
| Free Cash Flow Yield | 0.6% | 0.9% | 1.6% | 3.2% | 120.68% |
| Return on Equity | -7.6% | -7.6% | -2.0% | -1.7% | -73.75% |
| Total Debt | $70.68M | $54.34M | $53.70M | $52.63M | -26.28% |
BRKS earnings call for the period ending September 30, 2021.
BRKS earnings call for the period ending June 30, 2021.
BRKS earnings call for the period ending March 31, 2021.
BRKS earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
